During the past decade, RHMS La Madeleine ATH conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "RHMS La Madeleine ATH" #1 collaborator was "GlaxoSmithKline" with 3 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "RHMS La Madeleine ATH" are "Hepatitis B" (4 trials). Many other conditions were trialed in "RHMS La Madeleine ATH" in a lesser frequency.

Most popular intervention types in "RHMS La Madeleine ATH" are "Biological" (4 trials). Other intervention types were less common.

The name of intervention was led by "HBVAXPRO vaccine" (2 trials), "FENDRIX" (1 trials), "Fendrix vaccine" (1 trials), "HB-AS02V" (1 trials) and "HB-AS02V vaccine" (1 trials). Other intervention names were less common.

The vast majority of trials in "RHMS La Madeleine ATH" are 4 trials for "All" genders.

Currently, there are NaN active trials in "RHMS La Madeleine ATH". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in RHMS La Madeleine ATH, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in RHMS La Madeleine ATH, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".